Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis

Laropiprant did not demonstrate efficacy in asthmatic patients or patients with AR. Variations in PTGDR did not appear related to baseline asthma severity or treatment response (NCT00533208; NCT00783601).